Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
SAN FRANCISCO, Nov. 08, 2016 -- Hagens Berman Sobol Shapiro LLP reminds investors in Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) of the securities class action lawsuit and November 21, 2016 Lead Plaintiff deadline.
If you purchased or otherwise acquired securities of SPPI between February 28, 2013 and September 16, 2016 and suffered over $50,000 in losses contact Hagens Berman Sobol Shapiro LLP. For more information visit:
https://www.hbsslaw.com/cases/SPPI
or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing [email protected].
During Spectrum’s December 2012 meeting with the U.S. Food and Drug Administration, the FDA noted that one of Spectrum’s drugs, apaziquone, “did not meet the pre-specified criteria for superiority when compared to placebo” and discouraged submission of a New Drug Application.
Three years later, Spectrum submitted a New Drug Application based on similar studies provided to the FDA three years prior. Management repeatedly discussed apaziquone’s status during earnings conference calls but omitted information regarding the FDA’s prior discouragement. On September 14, 2016, the Company announced the FDA’s panel of outside experts found apaziquone had “not shown substantial evidence of a treatment effect over placebo,” sending Spectrum shares down 8% to close at $5.04 that day.
When TheStreet later reported “Spectrum joins an unacceptably long list of drug and biotech companies hurting investors by failing to be fully transparent about their communications with the FDA,” Spectrum shares fell another 2.6%.
“We are investigating the key details of apaziquone and the Company’s dealings with the FDA that Defendants apparently omitted,” said Hagens Berman partner Reed Kathrein.
Whistleblowers: Persons with non-public information regarding Spectrum Pharmaceuticals should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email [email protected].
About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the Firm and its successes can be found at www.hbsslaw.com. Read the Firm’s Securities Newsletter, and visit the blog. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact: Reed Kathrein, 510-725-3000
